CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for diseases of complement dysregulation and for orphan indications, today announced that data from the Company’s Phase 1 trial of its lead product candidate, RA101495, a synthetic macrocyclic peptide inhibitor of complement C5 for paroxysmal nocturnal hemoglobinuria (PNH), will be presented at the 21st Congress of the European Hematology Association (EHA) from June 9-12, 2016 in Copenhagen, Denmark.
